Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain

Life Sciences

Volumn 80, Issue 26, 2007, Pages 2454-2460

  Uchida, Shinya ^a   Kurosawa, Souhei ^a   Kato, Yoshihisa ^b   Nanri, Masato ^c   Yoshida, Kenichiro ^c  

^a Oki), Tomomi   (Japan)

^b TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bladder; Brain; L type calcium channel antagonist receptors; N oxide metabolites; Propiverine

Indexed keywords

1 METHYL 4 PIPERIDYL BENZILATE N OXIDE; 1 METHYL 4 PIPERIDYL DIPHENYLPROPOXYACETATE N OXIDE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DEETHYLOXYBUTYNIN; DILTIAZEM; DRUG METABOLITE; METHYL CHLORIDE; OXYBUTYNIN; PROPIVERINE; RADIOLIGAND; SCOPOLAMINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; BLADDER; BRAIN CORTEX; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; MALE; NONHUMAN; OVERACTIVE BLADDER; RAT;

ANALYSIS OF VARIANCE; ANIMALS; BENZILATES; BRAIN; CALCIUM CHANNELS, L-TYPE; DILTIAZEM; ISRADIPINE; MALE; MANDELIC ACIDS; N-METHYLSCOPOLAMINE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TRITIUM; URINARY BLADDER; VERAPAMIL;

RATTUS;

EID: 34249702870     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.04.002     Document Type: Article

References (38)

1. Alloussi S., Baldauf J., Derouet H., Zwergel U., and Meessen S. Effect of trospium chloride, oxybutynin and propiverine on the interaction of acetylcholine with isolated preparations of the human urinary bladder. Investigative Urology, 4 (1991) 157-161
2. Andersson K.E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacological Reviews, 45 (1993) 253-308
3. Chapple C.R. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology, 55 (2000) 33-46
4. Dorschner W., Stolzenburg J.U., Griebenow R., Halaska M., Schubert G., Mürts G., Frank M., and Wieners F. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. European Urology, 37 (2000) 702-708
5. 3H]nitrendipine with receptors for calcium antagonists in the cerebral cortex and heart of rats. Biochemical and Biophysical Research Communications, 104 (1982) 937-943
6. 2+ entry blockers to cardiac sarcolemmal membrane vesicles: characterization of diltiazem-binding sites and their interaction with dihydropyridine and aralkylamine receptors. Journal of Biological Chemistry, 261 (1986) 8146-8157
7. Godfraind T., Miller T., and Wibo M. Calcium antagonism and calcium entry blockade. Pharmacological Reviews, 38 (1986) 321-416
8. Halaska M., Dorschner W., and Frank M. Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourology and Urodynamics, 13 (1994) 428-430
9. Haruno A., Yamasaki Y., Miyoshi K., Miyake H., Tsuchiya K., Kosaka M., Nagai M., and Iriki M. Effects of propiverine hydrochloride and its metabolites on isolated guinea pig urinary bladder. Folia Pharmacologica Japonica, 94 (1989) 145-150
10. Haustein K.O., and Hüller G. On the pharmacokinetics and metabolism of propiverine in man. European Journal of Drug Metabolism and Pharmacokinetics, 13 (1988) 81-90
11. Hüller G., Haustein K.O., and Scheithauer S. Studies on the metabolic pattern of propiverine in urine after single administration. Die Pharmazie, 43 (1988) 91-95
12. Kaneko S., Haruno A., Suzuki N., Kitazato K., Yamazaki Y., Nagai M., Iriki M., Tsuchiya K., and Kosaka M. Effect of propiverine hydrochloride on the function of the bladder in dogs. Folia Pharmacologica Japonica, 93 (1989) 55-60
13. Kaneko S., Nakano D., Ohara M., and Nishimori T. Effects of propiverine hydrochloride (propiverine) on isolated rat and dog urinary bladder. Folia Pharmacologica Japonica, 113 (1999) 145-156
14. 3H](+)PN 200-110 binding to dihydropyridine receptors associated with calcium channels in rat cerebral cortex and heart. Life Sciences, 35 (1984) 721-732
15. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193 (1951) 265-275
16. Madersbacher H., and Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World Journal of Urology, 19 (2001) 324-335
17. Madersbacher H., Halaska M., Voigt R., Alloussi S., and Höfner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU international, 84 (1999) 646-651
18. Nomura N., Kaneko S., Hamakawa T., Nagai M., and Iriki M. Effects of propiverine hydrochloride (P-4) and its metabolites on urinary bladder function in anesthetized rats. Folia Pharmacologica Japonica, 94 (1989) 173-180
19. Oka T., Nakano K., Kirimoto T., and Matsuura N. Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats. Japanese Journal of Pharmacology 87 (2001) 27-33
20. Oki T., Kimura R., Saito M., Miyagawa I., and Yamada S. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. Journal of Urology, 172 (2004) 2059-2064
21. Palfreyman M.G., Dudley M.W., Cheng H.C., Mir A.K., Yamada S., Roeske W.R., Obata T., and Yamamura H.I. Lactamimides: a novel chemical class of calcium antagonists with diltiazem-like properties. Biochemical Pharmacology, 38 (1989) 2459-2465
22. Resnick N.M., and Yalla S.V. Management of urinary incontinence in the elderly. New England Journal of Medicine, 313 (1985) 800-805
23. 3H]Verapamil binding sites in brain and skeletal muscle: regulation by calcium. European Journal of Pharmacology, 95 (1983) 319-321
24. Riotte J., and Mutschler E. The spasmolytic activity of propiverine and some of its structural analogs. Arzneimittel-Forschung, 37 (1987) 300-302
25. Shimizu I., Kawashima K., Ishii D., and Oka M. Urodynamics in a rat neurogenic bladder model with a unilateral electrolytic lesion of the basal forebrain. BJU International, 91 (2003) 861-867
26. Stöhrer M., Madersbacher H., Richter R., Wehnert J., and Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord, 37 (1999) 196-200
27. Toide K., Yamamoto J., Murakami H., and Miyake H. General pharmacology of propiverine hydrochloride (P-4) (2) Effect on the central nervous system. Pharmacometrics, 37 (1989) 457-467
28. Tokuno H., Chowdhury J.U., and Tomita T. Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle. Naunyn-Schmiedeberg's Archives of Pharmacology 348 (1993) 659-662
29. 2+ channel. Journal of Cardiovascular Pharmacology, 6 (1984) S949-S955
30. Tsuda M., Yamamoto Y., Uda K., Shindo T., and Kawaguchi Y. Pharmacokinetic studies of propiverine hydrochloride (5): animal differences in vivo, in vitro and protein binding. Xenobiotic Metabolism and Disposition, 6 (1991) 3-20
31. Wada Y., Yoshida M., Kitani K., Kikukawa H., Ichinose A., Takahashi W., Gotoh S., Inadome A., Machida J., and Ueda S. Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder. Archives Internationales de Pharmacodynamie et de Thérapie, 330 (1995) 76-89
32. Wengler A., Schneider T., Zschiesche M., and Siegmund W. Studies on the metabolism of the bladder spasmolytic, propiverin (mictonorm) in humans. Die Pharmazie, 43 (1988) 652-653
33. Wuest M., Hecht J., Christ T., Braeter M., Schoeberl C., Hakenberg O.W., Wirth M.P., and Ravens U. Pharmacodynamics of propiverine and three of its main metabolites on detrusor contractions. British Journal of Pharmacology, 145 (2005) 608-619
34. 3H]PN 200-110 in coronary artery. Journal of Pharmacology and Experimental Therapeutics, 252 (1990) 327-332
35. Yamada S., Yamamura H.I., and Roeske W.R. Characterization of alpha-1 adrenergic receptors in the heart using [3H]WB4101: effect of 6-hydroxydopamine treatment. Journal of Pharmacology and Experimental Therapeutics, 215 (1980) 176-185
36. Yamamoto Y., Tsuda M., Uda K., Matsushita H., Shindo T., and Kawaguchi Y. Pharmacokinetic studies on propiverine hydrochloride. Metabolites in urinary bladder, other tissues and urine of rats-Xenobiotic Metabolism and Disposition, 10 (1995) 205-210
37. Yamamoto Y., Tsuda M., Uda K., Shindo T., and Kawaguchi Y. Pharmacokinetic studies of propiverine hydrochloride (1) Absorption, distribution and excretion after a single administration to rats. Xenobiotic Metabolism and Disposition, 5 (1989) 537-552
38. 3H]nitrendipine binding to calcium channel associated drug receptor sites in rat brain synaptosomes. Biochemical and Biophysical Research Communications, 108 (1982) 640-646